Literature DB >> 34901832

Antigen-Multimers: Specific, Sensitive, Precise, and Multifunctional High-Avidity CAR-Staining Reagents.

Yifei Hu1,2, Guoshuai Cao1, Xiufen Chen3, Xiaodan Huang1, Nicholas Asby1, Nicholas Ankenbruck1, Ali Rahman1, Ashima Thusu1, Yanran He4, Peter A Riedell4,3,5, Michael R Bishop3,5, Hans Schreiber6,4,5,7, Justin P Kline6,4,3,5, Jun Huang1,6,4.   

Abstract

Although chimeric antigen receptor (CAR) T-cell therapy has transformed cancer treatment, high-quality and universal CAR-staining reagents are urgently required to manufacture CAR T cells, predict therapy response, decipher CAR biology, and engineer new CARs. Here, we developed tetrameric and dodecameric forms of a multifunctional and extensible category of high-avidity CAR-staining reagents: antigen-multimers. Antigen-multimers detected CARs against CD19, HER2, and Tn-glycoside with significantly higher specificity, sensitivity, and precision than existing reagents. In addition to accurate CAR T-cell detection by flow cytometry, antigen-multimers also enabled ≥100-fold magnetic enrichment of rare CAR T cells, selective CAR T-cell stimulation, and high-dimensional CAR T-cell profiling by single-cell multi-omics analyses. Finally, antigen-multimers accurately captured clinical anti-CD19 CAR T cells from patients' cellular infusion products, post-infusion peripheral blood, and tumor biopsies. Antigen-multimers can be readily extended to other CAR systems by switching its antigen ligand. As such, antigen-multimers have broad clinical and research applications.

Entities:  

Keywords:  antigen-multimer; chimeric antigen receptor; detection; dodecamer; enrichment; extensible; sensitivity; single-cell omics; stimulation; tetramer

Year:  2021        PMID: 34901832      PMCID: PMC8654235          DOI: 10.1016/j.matt.2021.09.027

Source DB:  PubMed          Journal:  Matter        ISSN: 2590-2385


  49 in total

1.  Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable Antitumor Efficacy.

Authors:  Wentao Li; Shizhen Qiu; Jian Chen; Shutan Jiang; Wendong Chen; Jingwei Jiang; Fei Wang; Wen Si; Yilai Shu; Ping Wei; Gaofeng Fan; Ruijun Tian; Haitao Wu; Chenqi Xu; Haopeng Wang
Journal:  Immunity       Date:  2020-08-05       Impact factor: 31.745

2.  Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

Authors:  Jeremy S Abramson; M Lia Palomba; Leo I Gordon; Matthew A Lunning; Michael Wang; Jon Arnason; Amitkumar Mehta; Enkhtsetseg Purev; David G Maloney; Charalambos Andreadis; Alison Sehgal; Scott R Solomon; Nilanjan Ghosh; Tina M Albertson; Jacob Garcia; Ana Kostic; Mary Mallaney; Ken Ogasawara; Kathryn Newhall; Yeonhee Kim; Daniel Li; Tanya Siddiqi
Journal:  Lancet       Date:  2020-09-01       Impact factor: 79.321

3.  TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance.

Authors:  Yinmeng Yang; M Eric Kohler; Christopher D Chien; Christopher T Sauter; Elad Jacoby; Chunhua Yan; Ying Hu; Kelsey Wanhainen; Haiying Qin; Terry J Fry
Journal:  Sci Transl Med       Date:  2017-11-22       Impact factor: 17.956

Review 4.  CAR T cell immunotherapy for human cancer.

Authors:  Carl H June; Roddy S O'Connor; Omkar U Kawalekar; Saba Ghassemi; Michael C Milone
Journal:  Science       Date:  2018-03-23       Impact factor: 47.728

Review 5.  Tricks with tetramers: how to get the most from multimeric peptide-MHC.

Authors:  Linda Wooldridge; Anna Lissina; David K Cole; Hugo A van den Berg; David A Price; Andrew K Sewell
Journal:  Immunology       Date:  2009-02       Impact factor: 7.397

6.  Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.

Authors:  Alec J Walker; Robbie G Majzner; Ling Zhang; Kelsey Wanhainen; Adrienne H Long; Sang M Nguyen; Paola Lopomo; Marc Vigny; Terry J Fry; Rimas J Orentas; Crystal L Mackall
Journal:  Mol Ther       Date:  2017-07-01       Impact factor: 11.454

7.  Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL.

Authors:  John Rossi; Patrick Paczkowski; Yueh-Wei Shen; Kevin Morse; Brianna Flynn; Alaina Kaiser; Colin Ng; Kyle Gallatin; Tom Cain; Rong Fan; Sean Mackay; James R Heath; Steven A Rosenberg; James N Kochenderfer; Jing Zhou; Adrian Bot
Journal:  Blood       Date:  2018-06-12       Impact factor: 22.113

8.  Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR.

Authors:  Sara Ghorashian; Anne Marijn Kramer; Shimobi Onuoha; Gary Wright; Jack Bartram; Rachel Richardson; Sarah J Albon; Joan Casanovas-Company; Fernanda Castro; Bilyana Popova; Krystle Villanueva; Jenny Yeung; Winston Vetharoy; Aleks Guvenel; Patrycja A Wawrzyniecka; Leila Mekkaoui; Gordon Weng-Kit Cheung; Danielle Pinner; Jan Chu; Giovanna Lucchini; Juliana Silva; Oana Ciocarlie; Arina Lazareva; Sarah Inglott; Kimberly C Gilmour; Gulrukh Ahsan; Mathieu Ferrari; Somayya Manzoor; Kim Champion; Tony Brooks; Andre Lopes; Allan Hackshaw; Farzin Farzaneh; Robert Chiesa; Kanchan Rao; Denise Bonney; Sujith Samarasinghe; Nicholas Goulden; Ajay Vora; Paul Veys; Rachael Hough; Robert Wynn; Martin A Pule; Persis J Amrolia
Journal:  Nat Med       Date:  2019-09-02       Impact factor: 53.440

Review 9.  The kinetic-segregation model: TCR triggering and beyond.

Authors:  Simon J Davis; P Anton van der Merwe
Journal:  Nat Immunol       Date:  2006-08       Impact factor: 25.606

10.  Site-specific biotinylation of purified proteins using BirA.

Authors:  Michael Fairhead; Mark Howarth
Journal:  Methods Mol Biol       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.